United Therapeutics (UTHR) 10-Q2024 Q3 Quarterly report

Filed: 30 Oct 24, 6:32am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. sophomore Avg

New words: accrual, accuracy, await, begun, Benkowitz, biased, biopharmaceutical, capable, Christopher, commonly, confirmed, contend, controversial, deficient, delisted, disgorgement, Dwek, East, employed, examination, explanation, feedback, improperly, inadvertent, IND, intelligence, intervened, Lebanon, Michael, Patusky, poor, post, premarket, Raymond, shortly, software, sooner, substantively, tubing, voluntarily

Removed: allocated, asset, back, burden, Canadian, cancellation, ceased, compromised, convincing, dosage, endothelial, ETR, expansion, fee, fora, isolated, moving, nitric, Northern, notifying, oxide, parallel, patentability, preponderance, progenitor, proof, reached, rebuild, SAPPHIRE, Separately, stake, synthase, synthesizing, transfected, unpredictability, upheld, User, voting, write

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Associated UTHR transcripts

UTHR similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

EXHIBIT 32.2

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the quarterly report of United Therapeutics Corporation (the "Company") on Form 10-Q for the period ended September 30, 2024 as filed with the Securities and Exchange Commission (the "Report"), I, James C. Edgemond, Chief Financial Officer and Treasurer of the Company, certify, to the best of my knowledge, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

1.The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

2.The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.


October 30, 2024						/s/ JAMES C. EDGEMOND
						James C. Edgemond
						Chief Financial Officer and Treasurer
						(Principal Financial and Accounting Officer)
						United Therapeutics Corporation

THE FOREGOING CERTIFICATION IS BEING FURNISHED SOLELY PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 AND IS NOT BEING FILED AS PART OF THE FORM 10-Q OR AS A SEPARATE DISCLOSURE DOCUMENT.

A SIGNED ORIGINAL OF THIS WRITTEN STATEMENT REQUIRED BY SECTION 906, OR OTHER DOCUMENT AUTHENTICATING, ACKNOWLEDGING, OR OTHERWISE ADOPTING THE SIGNATURE THAT APPEARS IN TYPED FORM WITHIN THE ELECTRONIC VERSION OF THIS WRITTEN STATEMENT REQUIRED BY SECTION 906, HAS BEEN PROVIDED TO UNITED THERAPEUTICS CORPORATION AND WILL BE RETAINED BY UNITED THERAPEUTICS CORPORATION AND FURNISHED TO THE SECURITIES AND EXCHANGE COMMISSION OR ITS STAFF UPON REQUEST.

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.